Conditions Target antigen Participants Sponsor Phase Status Additional Comments Trial ID
Glioblastoma EGFRvIII 18 National Cancer Institute 1/2 Completed Patients received conditioning chemotherapy with cyclophosphamide and fludarabine followed by intravenous infusion of Aldesleukin. NCT01454596
Glioblastoma EGFRvIII 7 University of Pennsylvania 1 Active, Not Recruiting Patients receive combination therapy with pembrolizumab (PD-1 Inhibitor) and CAR T-cells. NCT03726515
R/R Brain Neoplasm IL13Rα2 18 City of Hope Medical Center 1 Recruiting Prior to CAR T therapy, patients receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine intravenously. NCT04510051
R/R Glioblastoma IL13Rα2 60 City of Hope Medical Center 1 Recruiting Patients receive nivolumab and ipilimumab intravenously, then receive CAR-T cells via Rickham catheter (ICV/intracranital ICT). NCT04003649
Diffuse Intrinsic Pontine and Midline Glioma B7-H3 70 Seattle Children’s Hospital 1 Recruiting CAR-T cells will be given via a CNS catheter into the tumor resection cavity or ventricular system. NCT04185038
R/R Glioblastoma B7-H3 12 Zhejiang University School of Medicine 1 Recruiting Patient receive Temozolomide orally, then CAR-T cells will be administrated via intratumoral or Intracerebroventricular injection. NCT04385173
R/R Brain Tumor HER2 28 Baylor College of Medicine 1 Recruiting CAR-T cells will be administered into the tumor, tumor resection cavity, and/or cerebrospinal fluid (CSF). NCT02442297
Recurrent Glioblastoma MMP2 36 City of Hope Medical Center 1 Recruiting Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR-T cells via dual delivery NCT04214392
High Grade Glioma GD2 32 Baylor College of Medicine 1 Recruiting Patients receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine. NCT04099797